Abstract
Smokers (≥10 cig/day; N =331) of European ancestry taking part in a double-blind placebo-controlled randomized trial of 12 weeks of treatment with bupropion plus counseling for smoking cessation were genotyped for a VNTR polymorphism in Exon-III of the Dopamine D4 receptor (DRD4) gene. Generalized estimating equations predicting point-prevalence abstinence at end of treatment and 2, 6, and 12-months post-end of treatment indicated that bupropion (vs. placebo) predicted increased odds of abstinence. The main effect of Genotype was not significant. A Genotype × Treatment interaction (p=.005) showed that bupropion predicted increased odds of abstinence in long-allele carriers (OR=1.31, p<.0001), whereas bupropion was not associated with abstinence among short-allele homozygotes (OR=1.06, p=.23). The Genotype × Treatment interaction remained when controlling for demographic and clinical covariates (p=.01) and in analyses predicting continuous abstinence (ps≤.054). Bupropion may be more efficacious for smokers who carry the long-allele, which is relevant to personalized pharmacogenetic treatment approaches.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
